BioWorld

May 17, 2010

Pharma Outlicensing: From Opportunism to R&D Funding

A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying. Read More

Money Raised Year to Date

Savient for Sale, Ardea Bid Adds Dose: Gout on Move

German Plan: Blood in Water for Overseas Reimbursement?

Money Raised By Biotech in 2010

Week in Review

Word on the Street

FDA Approvals in April

Phase I Clinical Trials Update: April 2010

Phase II Clinical Trials Update: April 2010

Pivotal/Phase III Clinical Trials Update: April 2010

Non-U.S. Clinical Trials And Regulatory Actions: April 2010

FDA Submissions, Approvals And Other Actions: April 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...